Dear,
RE: Investor focus remains firmly on a number of near-term catalysts: 1) Australian adultTGA clearance (expected 4QCY19); 2) children’s US FDA clearance (expected 4QCY19to early-1QCY20); and 3) initial commercialisation in EU/AUS (expected 2H20).
Would someone like to comment on the Upcoming catalysts listed above from a research paper published 30 October 2019? It seems that FDA results are not expected until December 2019 and commercialisation until second half of 2020.
Was any of this mentioned at the recent RAP meeting by any of the directors? I find it unusual that the research paper would be able to publish timelines such as these when it 'seems' that shareholders were expecting a much shorter time frame.
The above is promote discussion. Unfortunately, it comes on a RED day and should no way be considered down ramping.
To reassure I still hold my purchase from October 2015.
Thank you for taking the time to discuss.
Kind regards,
Raindear
Upcoming catalysts
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
